|
Name |
Peniciadametizine B
|
| Molecular Formula | C22H26N2O9S | |
| IUPAC Name* |
(3Z,6aS,7R,10R,10aS,11aR)-7,10,10a-trihydroxy-3-[(2-hydroxy-3,4-dimethoxyphenyl)methylidene]-2-methyl-11a-methylsulfanyl-6a,7,10,11-tetrahydropyrazino[1,2-b][1,2]benzoxazine-1,4-dione
|
|
| SMILES |
CN1/C(=C\C2=C(C(=C(C=C2)OC)OC)O)/C(=O)N3[C@](C1=O)(C[C@@]4([C@@H](C=C[C@H]([C@@H]4O3)O)O)O)SC
|
|
| InChI |
InChI=1S/C22H26N2O9S/c1-23-12(9-11-5-7-14(31-2)17(32-3)16(11)27)19(28)24-22(34-4,20(23)29)10-21(30)15(26)8-6-13(25)18(21)33-24/h5-9,13,15,18,25-27,30H,10H2,1-4H3/b12-9-/t13-,15-,18+,21+,22-/m1/s1
|
|
| InChIKey |
HBXKCYHTTYDURW-WDJDBVHOSA-N
|
|
| Synonyms |
Peniciadametizine B
|
|
| CAS | NA | |
| PubChem CID | 139587353 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 494.5 | ALogp: | -0.3 |
| HBD: | 4 | HBA: | 10 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 175.0 | Aromatic Rings: | 4 |
| Heavy Atoms: | 34 | QED Weighted: | 0.339 |
| Caco-2 Permeability: | -5.397 | MDCK Permeability: | 0.00001200 |
| Pgp-inhibitor: | 0.836 | Pgp-substrate: | 0.55 |
| Human Intestinal Absorption (HIA): | 0.944 | 20% Bioavailability (F20%): | 0.992 |
| 30% Bioavailability (F30%): | 0.987 |
| Blood-Brain-Barrier Penetration (BBB): | 0.489 | Plasma Protein Binding (PPB): | 75.63% |
| Volume Distribution (VD): | 0.969 | Fu: | 13.61% |
| CYP1A2-inhibitor: | 0.025 | CYP1A2-substrate: | 0.95 |
| CYP2C19-inhibitor: | 0.038 | CYP2C19-substrate: | 0.858 |
| CYP2C9-inhibitor: | 0.122 | CYP2C9-substrate: | 0.823 |
| CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.169 |
| CYP3A4-inhibitor: | 0.168 | CYP3A4-substrate: | 0.928 |
| Clearance (CL): | 4.563 | Half-life (T1/2): | 0.82 |
| hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.559 |
| Drug-inuced Liver Injury (DILI): | 0.947 | AMES Toxicity: | 0.736 |
| Rat Oral Acute Toxicity: | 0.155 | Maximum Recommended Daily Dose: | 0.017 |
| Skin Sensitization: | 0.307 | Carcinogencity: | 0.864 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
| Respiratory Toxicity: | 0.083 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004283 | ![]() |
0.613 | D03DIG | ![]() |
0.281 | ||
| ENC004282 | ![]() |
0.613 | D06GCK | ![]() |
0.268 | ||
| ENC003539 | ![]() |
0.610 | D0L1JW | ![]() |
0.265 | ||
| ENC004276 | ![]() |
0.589 | D04TDQ | ![]() |
0.255 | ||
| ENC003659 | ![]() |
0.538 | D01XWG | ![]() |
0.250 | ||
| ENC003546 | ![]() |
0.532 | D0F4ZY | ![]() |
0.243 | ||
| ENC003549 | ![]() |
0.529 | D01FFA | ![]() |
0.239 | ||
| ENC003545 | ![]() |
0.525 | D07VLY | ![]() |
0.238 | ||
| ENC004280 | ![]() |
0.513 | D0C9XJ | ![]() |
0.238 | ||
| ENC004281 | ![]() |
0.513 | D09DHY | ![]() |
0.237 | ||